Loading stock data…
CLDX
$32.31-0.57 (-1.73%)
Market ClosedLast close May 1
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Celldex Therapeutics, Inc. in the Healthcare sector is trading at $32.31. The stock is currently near its 52-week high of $35.79, remaining 21.6% above its 200-day moving average. Technical signals show neutral RSI of 48 and bearish MACD signal, explaining why CLDX maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 48) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$32.31
Potential Upside
5%
Whystock Fair Value$33.93
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus14 analysts
Mean target$57.00+76.4%
Range$34.00 – $90.00
Fundamentals
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific ant...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.68B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.20
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-49.08%
Volume
Today's trading volume
312,975
Recent News
Is Celldex Therapeutics (CLDX) Still Attractive After A 70% One Year Share Price Jump
If you are wondering whether Celldex Therapeutics at around US$33.29 is still offering value or starting to look stretched, the key is understanding what the current price actually reflects. The stock has been volatile in the short term, with a 3.6% decline over the last week, a 5.1% return over the past month, and a 23.3% return year to date, while the 1 year return sits at 70.1%. Recent attention on Celldex has centered on its role in the biotech space and investor interest in companies...
Celldex Therapeutics Spotlights Barzolvolimab as Phase III CSU Data Looms After Fast Enrollment
Celldex Therapeutics (NASDAQ:CLDX) executives used an appearance at H.C. Wainwright’s annual Inflammation and Skin Disease Conference to highlight the company’s late-stage plans for barzolvolimab, an anti-KIT monoclonal antibody being developed for chronic urticaria and other inflammatory skin disea
Celldex shares plunge after dumping $300 million stock deal
Celldex sells 10 million shares at a discount, stock craters
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday as Escalation Signals in Iran Conflict Lift Oil Prices
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 1.6%, and the actively t
Is Celldex’s US$300 Million Follow-On To Fund Barzolvolimab Altering The Investment Case For CLDX?
Celldex Therapeutics has completed a US$300.01 million follow-on offering of 10,345,000 common shares at US$29.00 each, adding fresh capital to support its pipeline. The raise closely follows encouraging Phase 2 barzolvolimab data in chronic urticaria, underscoring how investor capital is being directed toward late-stage, potentially disease-modifying assets. We’ll now examine how funding barzolvolimab’s commercial readiness shapes Celldex’s investment narrative and longer-term positioning...